Combination of cediranib and lenalidomide does not improve outcomes in advanced thyroid cancer

Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not make a difference in outcomes for treating patients with an advanced form of thyroid cancer that develops from thyroid follicular cells called differentiated thyroid cancer (DTC).

Orbital Therapeutics closes South San Francisco lab, eliminating some roles

Orbital Therapeutics, a well-funded biotech born out of buzzy base editing company Beam Therapeutics, has shuttered its South San Francisco office. The startup was unveiled

November 14, 2023

SARS-CoV-2-infection and vaccine-induced antibodies wane initially but stabilize for lasting protection

A study published in Immunity shows that antibody responses to SARS-CoV-2 infection and vaccination are long-lasting, with an initial decline followed by stabilization after seven

February 26, 2024

Two decades of data confirm Mediterranean diet cuts hypertension risk

Over a 20-year study, adherence to the Mediterranean diet significantly reduced the incidence of hypertension among adults initially free from the condition, emphasizing the diet’s

April 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.